The Jackson Laboratory (JAX In Vivo Services)
Nonprofit mouse genetics institute offering contract in vivo pharmacology using its own strains and humanized and PDX models across oncology, neuroscience, metabolism and immunology.
12 contract research organizations in our directory list Metabolic Disease Models as a capability, across 6 countries. 2 report GLP capability and 4 report AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.
Metabolic disease programs, and especially incretin-based and other obesity drugs, have made in vivo metabolic pharmacology one of the busiest areas of preclinical outsourcing. The standard workhorse is the diet-induced obese (DIO) mouse, alongside genetic models such as ob/ob and db/db mice and the ZDF rat, and chemically induced models such as streptozotocin for insulin-deficient diabetes.
Typical endpoints include body weight and food intake, body composition by EchoMRI or DEXA, oral or intraperitoneal glucose and insulin tolerance tests, fasting insulin and lipids, and energy expenditure by indirect calorimetry. Hyperinsulinemic–euglycemic clamps measure insulin sensitivity directly but need surgical catheterization and experienced staff, so relatively few labs offer them.
For MASH (formerly NASH) and liver fibrosis, models range from dietary approaches such as high-fat, high-fructose and high-cholesterol diets to choline-deficient diets and toxin-induced fibrosis, read out by histological activity and fibrosis scoring. Some labs also run spontaneously obese and diabetic nonhuman primates when rodent pharmacology does not translate.
Showing 12 CROs. Order rotates daily so no lab is permanently listed first.
Nonprofit mouse genetics institute offering contract in vivo pharmacology using its own strains and humanized and PDX models across oncology, neuroscience, metabolism and immunology.
OHSU national primate research center supporting neuroscience, metabolic, reproductive and infectious disease research, with core services available to outside investigators.
Integrated drug discovery CRO in Nottingham with in vivo pharmacology, DMPK and bioanalysis alongside chemistry and biology.
In vivo pharmacology CRO near Philadelphia running a broad catalog of efficacy models across CNS, pain, metabolic and inflammatory disease.
Preclinical CRO near Toulouse specializing in metabolic disease pharmacology, including obesity, diabetes and NASH/MASH models.
Tokyo CRO known for NASH/MASH and fibrosis mouse models, with efficacy studies across liver, kidney and metabolic disease.
Chinese provider of genetically engineered mouse models with in vivo pharmacology services across oncology, immunology and metabolic disease.
Shanghai provider of genetically engineered rodent models with phenotyping and in vivo pharmacology services.
Translational research company using Old World primate models for ophthalmology, CNS and metabolic disease studies, with an AAALAC-accredited primate facility.
AAALAC-accredited Japanese CRO specializing in nonhuman primate disease models for preclinical efficacy and proof of concept.
Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.
Danish preclinical CRO and peptide discovery company known for metabolic, liver and kidney disease models with AI-supported histology and 3D imaging readouts.